- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||lulizumab pegol|
|Search PubMed titles||lulizumab pegol|
|Search PubMed titles/abstracts||lulizumab pegol|
|Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody . PEGylation improves solubility and extends circulating half-life .
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.